PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Biochem Biophys Res Commun
; 414(3): 575-80, 2011 Oct 28.
Article
en En
| MEDLINE
| ID: mdl-21986528
Rho GDP dissociation inhibitor 2 (RhoGDI2) is a regulator of the Rho family GTPases. Recent work from our laboratory suggests that RhoGDI2 expression potentially enhances resistance to cisplatin as well as promotes tumor growth and malignant progression in gastric cancer. In this study, we demonstrate that phospholipase C-gamma (PLCγ) is required for RhoGDI2-mediated cisplatin resistance and cancer cell invasion in gastric cancer. The levels of phosphorylated PLCγ are markedly enhanced in RhoGDI2-overexpressing SNU-484 cells and, by contrast, repressed in RhoGDI2-depleted MKN-28 cells. Depletion of PLCγ expression or inhibition of its activity not only significantly increases cisplatin-induced apoptosis but also suppresses the invasive ability of RhoGDI2-overexpressing SNU-484 cells. Taken together, our results suggest that PLCγ plays a key role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer cells.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Gástricas
/
Cisplatino
/
Resistencia a Antineoplásicos
/
Inhibidores de Disociación de Guanina Nucleótido
/
Proteínas Supresoras de Tumor
/
Fosfolipasa C gamma
/
Antineoplásicos
Límite:
Humans
Idioma:
En
Revista:
Biochem Biophys Res Commun
Año:
2011
Tipo del documento:
Article
Pais de publicación:
Estados Unidos